6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by similar populations and methodology
Sandler, A., Reck, M., vonPawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Mezger, J., Moore, N., Manegold, C.Volume:
5
Language:
english
Journal:
European Journal of Cancer Supplements
DOI:
10.1016/S1359-6349(07)71398-8
Date:
September, 2007
File:
PDF, 58 KB
english, 2007